Mesoblast Clinches FDA Nod for Ryoncil®, Raises A$260M to Fuel Growth

• FDA approval granted for Ryoncil® to treat pediatric steroid-refractory acute graft versus host disease
• A$260 million capital raise completed to support clinical trial expansion and commercialization
• Commercial inventory and distribution network established with Cencora in the U.S.
• Ongoing Phase 3 trial for rexlemestrocel-L in chronic low back pain progressing